3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
veliparib
×
1 year
×
Clear all
No trials found.